Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 9.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,835 shares of the biopharmaceutical company’s stock after purchasing an additional 9,493 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Vanda Pharmaceuticals were worth $521,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $69,000. Zacks Investment Management acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $74,000. Price T Rowe Associates Inc. MD lifted its position in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 3,370 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of Vanda Pharmaceuticals by 59.5% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 9,180 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 5,459 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Ratings Changes

VNDA has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday. Finally, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the completion of the purchase, the chief executive officer now directly owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. This trade represents a 0.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have bought 32,000 shares of company stock worth $151,180. Company insiders own 10.00% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $3.93 on Friday. The company’s 50 day moving average price is $4.44 and its 200 day moving average price is $4.63. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $6.75. The firm has a market capitalization of $231.61 million, a price-to-earnings ratio of -12.28 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $50.04 million for the quarter, compared to analyst estimates of $45.13 million. Equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.